Bady, A., Saad Eldien, H., Hussein, O., Al sayed, M., Hetta, H., Abdelhaffez, A. (2022). Bone marrow Mesenchymal Stem Cells improve Cyclophosphamide-Induced Ovarian and Uterine Injury in Adult Female Rats via T-Cell modulation. Egyptian Journal of Histology, (), -. doi: 10.21608/ejh.2022.156450.1754
Amal Rateb Bady; Heba M Saad Eldien; Ola Hussein; Manal Al sayed; Helal Hetta; Azza Abdelhaffez. "Bone marrow Mesenchymal Stem Cells improve Cyclophosphamide-Induced Ovarian and Uterine Injury in Adult Female Rats via T-Cell modulation". Egyptian Journal of Histology, , , 2022, -. doi: 10.21608/ejh.2022.156450.1754
Bady, A., Saad Eldien, H., Hussein, O., Al sayed, M., Hetta, H., Abdelhaffez, A. (2022). 'Bone marrow Mesenchymal Stem Cells improve Cyclophosphamide-Induced Ovarian and Uterine Injury in Adult Female Rats via T-Cell modulation', Egyptian Journal of Histology, (), pp. -. doi: 10.21608/ejh.2022.156450.1754
Bady, A., Saad Eldien, H., Hussein, O., Al sayed, M., Hetta, H., Abdelhaffez, A. Bone marrow Mesenchymal Stem Cells improve Cyclophosphamide-Induced Ovarian and Uterine Injury in Adult Female Rats via T-Cell modulation. Egyptian Journal of Histology, 2022; (): -. doi: 10.21608/ejh.2022.156450.1754
Bone marrow Mesenchymal Stem Cells improve Cyclophosphamide-Induced Ovarian and Uterine Injury in Adult Female Rats via T-Cell modulation
Articles in Press, Accepted Manuscript, Available Online from 07 November 2022
1Human Anatomy and Embryology, College of Medicine, Assuit University
2College of medicine . Jouf University Saudi Arabia. 3Department of Histology and Cell Biology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
33Department of Histology and Cell Biology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt
43Department of Histology and Cell Biology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
5Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt;
6Department of Medical physiology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
Abstract
Background: Chemotherapeutic drugs, which are frequently employed to treat the rising number of cancer cases worldwide, have improved patient long-term survival. Despite the ability of chemotherapeutic agents to combat tumor cells, they have remarkable disadvantageous effects on numerous organs in the body, particularly those with antimitotic power. Aim: In the present study, the protective effects of Bone Marrow–Mesenchymal Stem Cells (BM-MSCs) treatment on Cyclophosphamide (CYP)-induced ovarian and uterine dysfunction and the underlying mechanisms were investigated. Moreover, the power of auto-healing following CYP administration was evaluated. Methods: Serum estrogen and follicle-stimulating hormone levels were detected by ELISA. The homing of the implanted mesenchymal cells was evaluated by protein expression of the rat Y chromosome-specific SRY gene. The expression levels of VEGF and caspase-3 were assessed by RT-qPCR. Immunohistochemical localization of CD3 (T cell activator) and PCNA were carried out. The oxidative stress status was assessed by estimation of MDA and GSH. Interleukin-1β (IL-1β) and interleukin-10 were investigated. Folliculogenesis and uterine morphological changes were evaluated by histopathological examination and morphometric analysis. Results: BM–MSC treatment alleviated disturbed hormonal secretion, folliculogenesis, and uterine morphological changes. The expression of VEGF, CD3, and PCNA increased while caspase-3 decreased. MDA and IL-1β levels decreased while GSH and IL-10 levels increased. However, for auto-healing group there was no remarkable improvement. Conclusion: Our results demonstrated the regenerative power, antioxidant activity, anti-inflammatory, and anti-apoptotic effects of BM-MSC therapy. In addition, our results elucidated the immunostimulatory influences of BM-MSC which partially participate in the regeneration of ovarian and uterine tissues. Furthermore, the present data revealed the difficulty of spontaneous recovery following CYP exposure, which highlighted the need for adjuvant therapy to improve female reproductive function.